title: Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.
abstract: The pharmacokinetics of single doses of cefaclor at 250 and 375 mg and cefuroxime axetil at 250 mg administered under optimal conditions (i.e., cefuroxime axetil after food and cefaclor in the fasted state) were studied in 24 healthy male volunteers. Drug concentrations in serum were related to MICs for common respiratory tract pathogens by using data generated from a recently completed national survey. The time the concentrations in serum exceeded the MICs for Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella (formerly Branhamella) catarrhalis were significantly greater (P less than 0.05) for cefuroxime axetil at 250 mg than for cefaclor at 250 or 375 mg. With the recommended dosing regimens (cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily), cefuroxime concentrations exceed the MIC for 90% of the strains tested for a greater time period than cefaclor concentrations with either regimen. The reasons for this difference are (i) the greater potency and slower clearance of cefuroxime compared with those of cefaclor and (ii) the greater sensitivity of these pathogens to cefuroxime.
authors.affiliation: Glaxo Inc. Research Institute, Research Triangle Park, North Carolina 27709.
authors.forename: N C
authors.initials: NC
authors.lastname: James
authors.forename: K H
authors.initials: KH
authors.lastname: Donn
authors.forename: J J
authors.initials: JJ
authors.lastname: Collins
authors.forename: I M
authors.initials: IM
authors.lastname: Davis
authors.forename: T L
authors.initials: TL
authors.lastname: Lloyd
authors.forename: R W
authors.initials: RW
authors.lastname: Hart
authors.forename: J R
authors.initials: JR
authors.lastname: Powell
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002433:Cefaclor / Q000097:blood / Q000493:pharmacokinetics*; D002444:Cefuroxime / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006193:Haemophilus influenzae / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008826:Microbial Sensitivity Tests; D009016:Moraxella / Q000187:drug effects; D010865:Pilot Projects; D011355:Prodrugs / Q000493:pharmacokinetics*; D013296:Streptococcus pneumoniae / Q000187:drug effects
chemical_list: D011355:Prodrugs; D002433:Cefaclor; D002444:Cefuroxime; C040738:cefuroxime axetil